drugset / Trial / NCT02453893

Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

NCT02453893

RandomizedParallel-groupTriple-blindTreatment

Summary

This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.

Timeline

Start
2013-11
Primary completion
2015-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloperidone Small molecule 12 mg Oral
Subject Iloperidone Small molecule 24 mg Oral
Comparator Risperidone Other / unclassified 3 mg Oral
Comparator Risperidone Other / unclassified 6 mg Oral

Indications